News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

New Study Shows Dogs Can be Trained to Sniff Out Presence of Prostate Cancer in Urine Samples

Determining how dogs do this may lead to biomarkers for new clinical laboratory diagnostics tests

Development of new diagnostic olfactory tools for prostate and other cancers is expected to result from research now being conducted by a consortium of researchers at different universities and institutes. To identify new biomarkers, these scientists are studying how dogs can detect the presence of prostate cancer by sniffing urine specimens.

Funded by a grant from the Prostate Cancer Foundation, the pilot study demonstrated that dogs could identify prostate samples containing cancer and discern between cancer positive and cancer negative samples.

This is not the only research study to focus on the ability of dogs to detect cancer and other health conditions. During the COVID-19 pandemic, dogs were used to spot people infected with the SARS-CoV-2 coronavirus. Dark Daily covered this in “German Scientists Train Dogs to Detect the Presence of COVID-19 in Saliva Samples; Can a Canine’s Nose Be as Accurate as Clinical Laboratory Testing?

The “end goal” of this latest pilot study is “to pave the way towards development of machine-based olfactory diagnostic tools that define and recapitulate what can be detected and accomplished now via canine olfaction,” according to a research paper published in the peer-reviewed journal PLOS ONE, titled, “Feasibility of Integrating Canine Olfaction with Chemical and Microbial Profiling of Urine to Detect Lethal Prostate Cancer.”

Research institutions, hospitals, and laboratories that participated in the pilot study included:

Canine Olfactory Combined with Artificial Intelligence Analysis Approach

The part of a canine brain that controls smell is 40 million times greater than that of humans. Some dog breeds have 300 to 350 million sensory receptors, compared to about five million in humans. With their keen sense of smell, dogs are proving to be vital resources in the detection of some diseases.

The pilot study examined how dogs could be trained to detect prostate cancer in human urine samples.

Claire Guest, CEO and Chief Scientific Officer of Medical Detection Dogs

Claire Guest, CEO and Chief Scientific Officer of UK-based Medical Detection Dogs and one of the study authors, is shown above with one of her cancer detecting dogs. In a Prostate Cancer Foundation article, she said, “Prostate cancer is not going to turn out to be a single note. What dogs are really good at discovering is a tune. Think of Beethoven’s Fifth Symphony, those first few notes. We suspect the cancer signature is something like that. It’s a pattern; the dogs are really good at recognizing the pattern. Machines that recognize the notes but can’t read the pattern are not reliable biomarkers,” she noted. The researchers believe the best solution for developing a clinical laboratory diagnostic that detects prostate cancer may be a combined approach using canine olfaction and AI neural networks. (Photo copyright: Janine Warwick/NPR.)

To perform the study, the researchers trained two dogs to sniff urine samples from men with high-grade prostate cancer and from men without the cancer. The two dogs used in the study were a four-year-old female Labrador Retriever named Florin, and a seven-year-old female wirehaired Hungarian Vizsla named Midas. The dogs were trained to respond to cancer-related chemicals, known as volatile organic compounds, or VOCs, the researchers added to the urine samples, and to not respond to the samples without the VOCs.

Both dogs performed well in their cancer detection roles, and both successfully identified five of seven urine samples from men with prostate cancer, correlating to a 71.4% accuracy rate. In addition, Florin correctly identified 16 of 21 non-aggressive or no cancer samples for an accuracy rate of 76.2% and Midas did the same with a 66.7% accuracy rate.

The researchers also applied gas chromatography-mass spectroscopy (GC-MS) analysis of volatile compounds and microbial species found in urine.

“We wondered if having the dogs detect the chemicals, combined with analysis by GC-MS, bacterial profiling, and an artificial intelligence (AI) neural network trained to emulate the canine cancer detection ability, could significantly improve the diagnosis of high-grade prostate cancer,” said Alan Partin, MD, PhD, Professor of Urology, Pathology and Oncology, Johns Hopkins University School of Medicine and one of the authors of the study, told Futurity.

The researchers determined that canine olfaction was able to distinguish between positive and negative prostate cancer in the samples, and the VOC and microbiota profiling analyses showed a qualitative difference between the two groups. The multisystem approach demonstrated a more sensitive and specific way of detecting the presence of prostate cancer than any of the methods used by themselves.

In their paper, the researchers concluded that “this study demonstrated feasibility and identified the challenges of a multiparametric approach as a first step towards creating a more effective, non-invasive early urine diagnostic method for the highly aggressive histology of prostate cancer.”

Can Man’s Best Friend be Trained to Detect Cancer and Save Lives?

Prostate cancer is the second leading cause of cancer deaths among men in the developed world. And, according to data from the National Cancer Institute, standard clinical laboratory blood tests, such as the prostate-specific antigen (PSA) test for early detection, sometimes miss the presence of cancer.

Establishing an accurate, non-invasive method of sensing the disease could help detect the disease sooner when it is more treatable and save lives.

The American Cancer Society estimates that there will be about 248,530 new cases of prostate cancer diagnosed in 2021 and that there will be approximately 34,130 deaths resulting from the disease during the same year.

Of course, more testing will be needed before Man’s best friend can be put to work detecting cancer in medical environments. But if canines can be trained to detect the disease early, and in a non-invasive way, more timely diagnosis and treatment could result in higher survival rates.

Meanwhile, as researchers identify the elements dogs use to detect cancer and other diseases, this knowledge can result in the creation of new biomarkers than can be used in clinical laboratory tests.

JP Schlingman

Related Information:

Feasibility of Integrating Canine Olfaction with Chemical and Microbial Profiling of Urine to Detect Lethal Prostate Cancer

German Scientists Train Dogs to Detect the Presence of COVID-19 in Saliva Samples; Can a Canine’s Nose Be as Accurate as Clinical Laboratory Testing?

Olfactory Sensations! Meet the Dogs Leading the Revolution in Prostate Cancer Detection (Part 1)

Olfactory Sensations Smell Like Cancer (Part 2)

Prostate Cancer-Detecting Dogs’ Olfactory Capacity Trains Neural Network for Combination Diagnostic Approach

Dogs Sniff Pee for Signs of Prostate Cancer

Thailand Researchers Train Labrador Retrievers to Detect COVID-19 in Human Sweat

University of East Anglia Researchers Develop Non-Invasive Prostate Cancer Urine Test

CMS Missed 96 Hospitals with Suspected HAI Reporting Due to Limited Use of Analytics, OIG Report Reveals

OIG suggests better use of analytics by CMS could prevent gaming of the system by providers; clinical laboratories can help through test utilization management technology

It may come as a surprise to many hospital-based pathologists and clinical laboratory managers that the Centers for Medicare and Medicaid Services (CMS) has reason to suspect that some hospitals are “gaming” the system in how they report hospital-acquired infections (HAIs).

In 2015, CMS implemented the Hospital-Acquired Condition Reduction Program (HACRP) as part of the Patient Protection and Affordable Care Act (ACA). The HACRP program incentivizes hospitals to lower their HAI rates by adjusting reimbursements according to the inpatient quality reporting (hospital IQR) data provided by the healthcare providers. Hospital IQR data is the basis on which CMS validates a hospital’s HAI rate (among other things CMS is tracking) to determine the hospital’s reimbursement rate for that year.

However, an April 2017 report by the Office of the Inspector General US Department of Health and Human Services (OIG) noted that CMS was not doing enough to identify and target hospitals with abnormal reporting of HAIs.

The OIG reported:

  • CMS, in 2016, met its regulatory requirement to validate inpatient quality reporting data;
  • It reviewed data of 400 randomly selected hospitals as well as 49 hospitals targeted for failing to report half their HAIs, or for low scores in the prior year’s validation process;

However, OIG also reported that CMS did not include hospitals that displayed abnormal data patterns in its targeted sample. Targeting those hospitals, according to the OIG, could identify inaccurate reporting.

CMS staff had identified 96 hospitals with aberrant data patterns, but did not target them for validation—even though the agency can select up to 200 targeted hospitals for review, Becker’s Hospital Review pointed out.

Dollars More Important than Deaths

According to the OIG report, Medicare excluded in its investigation dozens of hospitals with suspected HAI reporting. This is odd since the CMS and the Centers for Disease Control (CDC) apparently are aware that some healthcare providers have manipulated data to improve their quality measure scores and thus increase their reimbursement rates.

“Collecting and analyzing quality data is increasingly central to Medicare programs that link payments to quality and value. Therefore, it is important for CMS to ensure that hospitals are not gaming [manipulating data to improve scores] their reporting of quality data,” the OIG report noted.

“There are greater requirements for what a company says about a washing machine’s performance than there is for a hospital on quality of care. And this needs to change,” stated Peter Pronovost, MD, PhD, in the Kaiser Health News article. “We require auditing of financial data, but we don’t require auditing of healthcare quality data, and that implies that dollars are more important than deaths.” Pronovost is Senior Vice President for Patient Safety and Quality at Johns Hopkins University School of Medicine.

 

Peter Pronovost, MD, PhD

Peter Pronovost, MD, PhD (above) testifying on preventable deaths before the Senate Subcommittee on Primary Health and Aging in 2014. He is Senior Vice President for Patient Safety and Quality at Johns Hopkins University School of Medicine in Baltimore. Pronovost told Kaiser Health News that there are no uniform standards for reviewing data that hospitals report to Medicare. (Photo copyright: US Senate Committee on Health, Education, Labor and Pensions.)

Medicare Missed Hospitals with Suspected HAI Data

CMS should have done an in-depth review of many hospitals that submitted “aberrant data patterns” in 2013 and 2014, the OIG stated in its report. According to a Kaiser Health News article, such patterns could include:

  • A rapid change in results;
  • Improbably low infection rates; and
  • Assertions that infections nearly always struck before patients arrived at the hospital.

“There’s a certain amount of blind faith that hospitals are going to tell the truth. It’s a bit much to expect that if they had a bad record they are going to fess up to it,” noted Lisa McGiffert, Director of the Safe Patient Project at Consumers Union, in the Kaiser Health News article.

CMS Needs Better Data Analytics

So, what does the OIG advise CMS to do? The agency called for “better use of analytics to ensure the integrity of hospital-reported quality data.” Specifically, OIG suggested CMS:

  • Identify hospitals with abnormal percentages of patients who had infections on admission;
  • Apply risk scores to identify hospitals with high propensity to manipulate reporting;
  • Use experiences to create and improve models that identify hospitals most likely to game their reporting.

CMS’ Administrator Seema Verma reportedly responded, “We will continue to evaluate the use of better analytics as feasible, based on Medicare’s operational capabilities.”

Medical Laboratory Diagnostic Testing Part of Gaming the System

A 2015 CMS/CDC joint statement noted “three ways that hospitals may be deviating from CDC’s definitions for reportable HAIs,” and two involve diagnostic test ordering. According to the OIG report, they include:

  • Overculturing: Diagnostic tests may be overutilized by providers in absence of clinical symptoms. Hospitals may use positive results to game their data by claiming infections that appeared days later were present on admission and thus not reportable.
  • Underculturing: Hospitals underculture when they do not order diagnostic tests in the presence of clinical symptoms. By not ordering the test, the hospital does not learn whether the patient truly has an infection and, therefore, the hospital does not have to report it.
  • Adjudication: Hospital administrative staff may inappropriately overrule those who report infections. HAIs are, therefore, not shared.

Clinical Laboratories Can Help

One in 25 people each day receives an HAI, CDC estimates. The OIG findings should be a reminder to medical laboratories and pathology groups that quality measures and patient outcomes are often transparent to media, patients, and the public.

One way medical laboratories in hospitals and health systems can help is by investing in utilization management technology and protocols that ensure appropriate lab test utilization. Informing doctors on the availability of appropriate diagnostic tests based on patients’ existing conditions, unique physiologies, or medical histories, could help prevent hospitals from inadvertently or deliberately game the system.

Clearly, transparency in healthcare is increasing. That means there will be more news stories revealing federal agencies’ failures to respond to healthcare data in ways that could have protected patients and the public. Clinical laboratories don’t want to be included in negative reporting.

—Donna Marie Pocius

Related Content:

CMS Validated Hospital Inpatient Quality Reporting Program Data, But Should Use Additional Tools to Identify Gaming

Medicare Failed to Investigate Suspicious Infection Cases from 96 Hospitals

CMS Can Do More to Validate Hospital-Reported Infection Data, OIG Report Finds

Study Suggests Medical Errors Now Third Leading Cause of Death in the US

Research Study at Johns Hopkins University Reveals CDC Does Not Record Medical Errors in Annual Mortality Report, Yet Such Errors Are Third Leading Cause of Death

Biggest Opportunity for Clinical Laboratory Industry is Utilization Management of Lab Tests, But Only If It Is Done Well

Lessons from the Pioneers: Reporting Healthcare-Associated Infections

Webinar: Simple, Swift Approaches to Lab Test Utilization Management: Proven Ways for Your Clinical Laboratory to Use Data and Collaborations to Add Value 

Research Study at Johns Hopkins University Reveals CDC Does Not Record Medical Errors in Annual Mortality Report, Yet Such Errors Are Third Leading Cause of Death

An earlier Johns Hopkins study looked at diagnostic errors and determined that such errors were the leading cause of malpractice payouts. Can clinical laboratories help?

At a time of heightened transparency in healthcare outcomes, a Johns Hopkins University School of Medicine (Johns Hopkins) study makes a startling conclusion: medical errors are an under-recognized cause of patients’ deaths in the United States. In fact, medical errors rank third—after heart disease and cancer—in causing patients’ deaths, according to a Johns Hopkins statement.

This finding has many implications for pathologists and clinical laboratory managers. Often, medical errors are associated with the failure of physicians to order correct medical laboratory tests at critical junctures. Alternatively, a medical error can result if the physician fails to take appropriate action after getting an accurate lab test result. Thus, any effort within the health system to reduce medical errors will probably bring pathologists and medical laboratory scientists into closer consultation with clinicians.

What the researchers at Johns Hopkins also learned during their study is that medical error is not reported as a cause of death on death certificates. Further, the Centers for Disease Control and Prevention (CDC) has no “medical error” category in its annual report on deaths and mortality, The New York Times (NYT) reported. (more…)

Recent Study Estimates that 5% of Patients in Outpatient Settings Are Misdiagnosed, Offering Pathologists an Opportunity to Provide More Consultations to Doctors

This spring, researchers at the VA Hospital in Houston published a study revealing that one in 20 patients in outpatient settings are misdiagnosed

Publication of new peer-reviewed clinical studies indicates that, within the United States, more than 5% of outpatients—or 12 million people—are misdiagnosed annually. Few pathologists and clinical laboratory scientists would dispute this number because every day they see the best and the worst of how physicians use medical laboratory tests.

These findings were reported in a study published in the April edition of the British Medical Journal, BMJ Quality & Safety. (more…)

Academic Pathologists at the University of Minnesota Developing for Innovative Ways to Add Value for Patients Using Advanced Expertise in Clinical Pathology Test Services

Department of Laboratory Medicine and Pathology at the University of Minnesota is anticipating new clinical and operational needs of physicians practicing in ACOs and medical homes

MINNEAPOLIS, MINNESOTA—Academic pathology departments are facing a host of challenges as a direct result of the rapid pace of change happening today in the U.S. healthcare system. Some challenges are financial because of reduced funding. Other challenges are clinical or due to the formation of ACOs and similar types of integrated-care delivery organizations. (more…)

;